Recent Blog Articles
Poverty, homelessness, and social stigma make addiction more deadly
Sugar: How sweet it is... or is it?
Cardiovascular safety from prostate cancer drugs remains uncertain
Rising alcohol use among older adults
Easily distracted? Try meditation
Harvard Health Ad Watch: Can a wearable device reduce stress?
Is metformin a wonder drug?
Listening to your hunger cues
Does your child need to bathe every day?
Can flavonoids help fend off forgetfulness?
Coronavirus Resource Center
As coronavirus continues to spread, many questions and answers
Learn more about:
Below, you'll find answers to common questions all of us are asking. We will be adding new questions and updating answers as reliable information becomes available. Also see our blog posts featuring experts discussing coronavirus and COVID-19 and our glossary for relevant terms.
New questions and answers
Do I need a COVID vaccine booster shot?
In September 2021, the CDC recommended a booster dose of the COVID-19 vaccine for certain groups of Pfizer/BioNTech vaccine recipients. Earlier this month, the FDA had authorized use of a booster dose in these populations. Those eligible for a booster need to wait at least six months after completion of the initial two-dose mRNA vaccine series before they get the third shot.
Specifically, the CDC recommends the following groups should get a booster dose:
- people 65 years and older
- residents in long-term care settings
- people ages 50 to 64 with underlying medical conditions that put them at increased risk for severe COVID illness.
In addition, the CDC recommends that the following groups may get a booster dose:
- People ages 18 to 49 with underlying medical conditions that put them at increased risk for severe COVID illness
- People ages 18 to 64 who are at increased risk for COVID-19 exposure and transmission because of their occupational or institutional setting.
Although the Pfizer/BioNTech vaccine is approved for people ages 16 years and older, the CDC did not recommend a booster dose for 16- and 17-year-olds with underlying medical conditions that may increase their risk for severe COVID. This may be, in part, because male teens and young adults have been found to have a higher-than-normal risk of heart inflammation following vaccination with the mRNA COVID-19 vaccines.
In addition, this booster recommendation does not apply to people who initially received the Moderna or Johnson & Johnson vaccines.
When will children be able to get the COVID-19 vaccine?
In September 2021, Pfizer/BioNTech announced that its COVID-19 vaccine is safe and effective in children ages 5 to 11 years. The company reported its study results via press release; the data have not been peer reviewed or published. Pfizer plans to submit its data to the FDA and apply for emergency use authorization (EUA) for this age group within the next few weeks.
In the Pfizer study, 2,268 children, ages 5 to 11, received two doses of the COVID-19 vaccine, spaced three weeks apart, while a smaller group of children received a placebo. The children in this study were given 10 microgram doses of the vaccine, which is lower than the 30 microgram doses being given to Pfizer vaccine recipients ages 12 years and older. (Earlier results had found increased side effects for the younger children at the higher dose.) Antibody responses and side effects in the 5-to-11-year-olds were compared to those of 16-to 25-year-old participants from a previous study.
The trial results showed that the antibody response in 5-to-11-year-olds was similar to the antibody response in teens and young adults. Side effects were also comparable. There were not enough COVID cases in the study population to tell whether the vaccine protected against infection or illness.
In May 2021, the FDA expanded its EUA for the Pfizer/BioNTech COVID-19 vaccine to include adolescents 12 to 15 years old. Previously, the Pfizer vaccine was authorized for use in children 16 years and older, while the Moderna and Johnson & Johnson vaccines are authorized for people 18 years and older.
In June 2021, Moderna applied to the FDA for EUA of their mRNA vaccine for use in children ages 12 to under 18 years. The company announced promising results of a Phase 2/3 study in adolescents in May. The study enrolled 3,732 children ages 12 to 17. Two-thirds received two doses of the Moderna mRNA vaccine and one-third received a placebo. The immune response generated by the vaccine in adolescents was found to be at least as good as the immune response the vaccine generated in adults. Starting two weeks after the second vaccine dose, no cases of COVID-19 occurred in the vaccine group, compared to four cases in the placebo group. Vaccine side effects were mild to moderate, with injection site pain, headache, fatigue, muscle pain, and chills being the most common. The study did not identify any significant safety concerns. The results were announced in a press release. Moderna is also studying the vaccine in children between the ages of 6 months and 12 years.
Age de-escalation studies, in which the vaccines are tested in groups of children of descending age, are done to confirm that the vaccines are safe and effective for each age group. They also identify the optimal dose, which must be effective, but with tolerable side effects.
The FDA reviews data from the de-escalation trials to decide whether to authorize the vaccines for each age group.
Does vaccination protect against long COVID?
Being fully vaccinated with a COVID-19 vaccine does reduce the risk of long COVID. Also called post-COVID-19 syndrome or post-acute sequelae of SARS-CoV-2 infection (PASC), long COVID is the term for symptoms that arise or persist more than 28 days after an initial COVID-19 infection.
Vaccination may reduce the risk of long COVID in two ways. The first is by reducing the risk of becoming infected with COVID in the first place. But what about people who experience breakthrough infections, becoming infected despite being vaccinated?
A study published in The Lancet shows that fully vaccinated people who experience breakthrough infections are about 50% less likely to develop long COVID than people who are infected without having been vaccinated. These results are based on self-reported data submitted via the COVID Symptom Study phone app in the United Kingdom between December 2020 and July 2021.
The FDA has granted full approval to the Pfizer/BioNTech COVID-19 vaccine. How is this different from emergency use authorization?
In August 2021, the FDA granted full approval to the Pfizer/BioNTech COVID-19 mRNA vaccine for use in people ages 16 years and older. The transition from emergency use authorization (EUA) status to full licensure was based on additional data and longer follow-up showing that the vaccine met certain safety, effectiveness, and manufacturing quality standards. The Pfizer/BioNTech vaccine can now be marketed under the brand name Comirnaty.
In granting full approval, the FDA analyzed data from 44,000 study participants. Half received two doses of the Pfizer/BioNTech vaccine and the other half received the placebo. Over six months of follow-up, the vaccine was 91.1% effective at preventing symptomatic COVID-19 infection.
A subset of study participants was followed for six months to look at safety outcomes associated with the vaccine. A small but increased risk of two inflammatory heart conditions, myocarditis and pericarditis, was identified and will be noted in the FDA’s prescribing information. The risk is higher in males under age 40, and highest in males ages 12 to 17. Safety data will continue to be collected and monitored.
Before granting full approval, the FDA also inspected vaccine manufacturing facilities to ensure vaccine quality. Full approval gives doctors some leeway to prescribe the vaccine for "off-label use."
In the US, more than 92 million people have been fully vaccinated with the Pfizer/BioNTech vaccine since it received EUA in December 2020. Children ages 12 to 15 years will continue to use the vaccine under EUA status.
EUA status may be granted by the FDA during public health emergencies when they determine that the known and potential benefits of a medical product — in this case, the COVID-19 vaccine — outweigh the known and potential risks.
How long will protection from the COVID-19 vaccines last?
Three studies released by the CDC in August 2021 suggest that the COVID-19 mRNA vaccines (Pfizer/BioNTech and Moderna) become less effective over time. The studies, all published in MMWR, show that vaccine protection against mild to moderate infection begins to drop beginning several months after the second dose. However, the vaccines continue to be highly protective against severe illness, hospitalization, and death.
The increase in mild and moderate breakthrough infections may not be entirely due to a decrease in the immunity provided by the vaccines. It’s possible the vaccines are not as effective against the Delta variant as they were against previous variants. And safety precautions such as mask wearing and physical distancing have also decreased in the past several months. All these factors may play into increased breakthrough infections in fully vaccinated people.
The MMWR studies did not address the effectiveness of the Johnson & Johnson vaccine over time.
I have a weakened immune system. Do I need a third dose of the COVID-19 vaccine?
In August 2021, the FDA authorized a third dose of an mRNA vaccine (Pfizer/BioNTech or Moderna) for certain people who are immunocompromised. The third dose should be given at least 28 days after the second dose.
The COVID-19 vaccines, like other vaccines, work by stimulating a person’s immune system to produce antibodies against the virus. If the antibodies later encounter the actual virus, they are ready to recognize and destroy it.
A person with a weakened immune system may not be able to produce a strong enough immune response to the standard, two-dose COVID mRNA vaccine regimen. This leaves them more likely to have a breakthrough infection, and increases the risk of more severe disease if they do become infected. A third vaccine dose may enhance the immune response in some people who are immunocompromised.
The FDA authorized a third dose for people who are moderately to severely immunocompromised. A person may have a weakened immune system for a variety of reasons. These include being born with an immunodeficiency, having advanced or untreated HIV, and having a chronic medical condition such as chronic kidney disease or lack of a spleen. Many types of medication also suppress the immune response, including some cancer treatments, TNF blockers, some biologic agents, and high-dose corticosteroids. Talk to your doctor if you think you may qualify for a third COVID vaccine dose.
The FDA and CDC further recommend that anyone with a weakened immune system should continue to wear masks, stay six feet apart from others, and avoid crowds and poorly ventilated indoor spaces.
Click here for more new questions and answers.
Symptoms, spread, and other essential information
What is coronavirus and how does it spread? What is COVID-19 and what are the symptoms? How long does coronavirus live on different surfaces? Take a moment to reacquaint yourself with basic information about this virus and the disease it causes.
Click here to read more about COVID-19 symptoms, spread, and other basic information.
Social distancing, hand washing, and other preventive measures
By now, many of us are taking steps to protect ourselves from infection. This likely includes frequent handwashing, regularly cleaning frequently touched surfaces, and social distancing. How do each of these measures help slow the spread of this virus, and is there anything else you can do?
Click here to read more about what you can do to protect yourself and others from coronavirus infection.
If you are at higher risk
Though no one is invulnerable, we've seen that older adults are at increased risk for severe illness or death from COVID-19. Underlying conditions, including heart disease, lung disease, and diabetes, increase risk even further in those who are older. In addition, anyone with an underlying medical condition, regardless of their age, faces increased risk of serious illness.
Click here to read more about what you can do if you are at increased risk for serious illness.
If you've been exposed, are sick, or are caring for someone with COVID-19
Despite your best efforts, you may be exposed to coronavirus and become ill with COVID-19. Or you may be in a position where you are caring for a loved one with the disease. It's important to know what to do if you find yourself in any of these situations. Stock up with medications and health supplies now, and learn the steps you can take to avoid infecting others in your household and to avoid getting sick yourself if you are caring for someone who is ill.
Click here to read more about what to do you if you have been exposed, are sick, or are caring for someone with COVID-19.
Treatments for COVID-19: What helps, what doesn't, and what's in the pipeline
While there are no specific treatments for COVID-19 at this time, there are things you can do to feel better if you become ill. In the meantime, researchers around the globe are looking at existing drugs to see if they may be effective against the virus that causes COVID-19, and are working to develop new treatments as well.
Click here to read more about measures that can help you feel better and treatments that are under investigation.
Coronavirus and kids
So far, the vast majority of coronavirus infections have afflicted adults. And when kids are infected, they tend to have milder disease. Still, as a parent, you can't help but worry about the safety of your children. Many parents are also trying to find a balance between answering their children's questions about the pandemic and enforcing health-promoting behaviors and social distancing rules without creating an atmosphere of anxiety. Not to mention keeping kids engaged and entertained with schools closed and playdates cancelled.
Click here to read more about kids and the coronavirus outbreak.
Coping with coronavirus
The news about coronavirus and its impact on our day-to-day lives has been unrelenting. There's reason for concern and it makes good sense to take the pandemic seriously. But it's not good for your mind or your body to be on high alert all the time. Doing so will wear you down emotionally and physically.
Click here to read more about coping with coronavirus.
I recently spent time with someone who tested positive for COVID-19. I’m fully vaccinated. Do I need to get tested?
Yes, you do. In July 2021, the CDC recommended that anyone who is fully vaccinated and comes into contact with someone who has, or is suspected of having, COVID-19 should get tested three to five days after exposure. In addition, you should wear a mask in public indoor settings for 14 days or until you receive a negative test result. If you are vaccinated, you do not need to quarantine, but you should isolate if you develop symptoms or receive a positive test result.
Previously, the CDC had said that someone who was fully vaccinated only needed to get tested after exposure if they were experiencing symptoms. The change follows new evidence regarding the Delta variant, which shows that people who are vaccinated and then get infected (breakthrough infections) can spread the virus to others, perhaps to the same extent as those who are unvaccinated.
If you are not fully vaccinated, a 14-day quarantine remains the best way to avoid spreading the virus to others after you've been exposed to someone with COVID-19. According to CDC guidelines, you may discontinue quarantine after a minimum of 10 days if you do not have any symptoms, or after a minimum of seven days if you have a negative COVID test within 48 hours of when you plan to end quarantine.
What do I need to know about the Delta variant?
The Delta variant is different from previous SARS-CoV-2 variants that have made their way to the US. It’s highly contagious and may cause more severe disease. It is also more likely than previous variants to be spread by vaccinated people experiencing breakthrough infections.
Evidence presented to the CDC showed the Delta variant to be much more contagious than previous variants, with a risk of transmission similar to chickenpox. It also appears that people who are infected can spread the virus for longer periods of time.
In addition, people who are vaccinated and then get infected (breakthrough infections) can also spread the virus to others, perhaps to the same extent as those who are unvaccinated. This is also new; vaccinated people were much less likely to spread previous variants.
Finally, international studies point to the Delta variant being more likely to cause severe disease.
The good news is that while vaccination may be less effective at preventing infection and spread of the Delta variant, it is still highly protective against severe disease, hospitalization, and death. Get the COVID-19 vaccine if you have not already done so.
In July 2021, the CDC advised all people — vaccinated and unvaccinated — to wear masks in public indoor places, in areas of the country with substantial or high transmission of the virus. Given the threat posed by the Delta variant, it’s reasonable for everyone to start wearing a mask in indoor public spaces, regardless of the level of virus in your area.
Masks reduce the amount of virus we breathe in, and breathe out. Combined with the vaccine, masks provide a one-two punch that reduces the risk of spread — to children who are not yet eligible for vaccines, to people with weakened immune systems, and to others who are unvaccinated. Masks also provide additional protection for the wearer, including who are fully vaccinated.
Why is the CDC asking fully vaccinated people to wear masks again? Where and when do I need to wear a mask now?
In July 2021, the CDC advised all people — vaccinated and unvaccinated — to wear masks in public indoor places, in areas with substantial or high transmission of the virus. The CDC has always advised unvaccinated people to mask indoors, and also advises anyone at increased risk to wear a mask indoors, regardless of the level of community transmission. The change in guidance for people who are fully vaccinated was made amidst increasing numbers of infections and hospitalizations across the country.
One factor driving increased infections is the rise of the Delta variant, which spreads more easily than other variants. The Delta variant is now the dominant variant in the US.
We know that people who are fully vaccinated have a much smaller risk of getting sick if they are exposed the Delta variant. While they are also less likely to spread the virus, the Delta variant is more capable than the original virus of getting into cells that line the nose, mouth, and throat. Once these variants get inside the cells, they rapidly make copies of themselves, increasing what is called the viral load. That’s why people who are fully vaccinated can still carry greater amounts of the Delta variant, making it more likely that they could spread the virus to others.
This is where the new masking guidelines come in. Masks reduce the amount of virus we breathe in, and breathe out. Combined with the vaccine, masks provide a one-two punch that reduces the risk of spread — to children who are not yet eligible for vaccines, to people with weakened immune systems, and to others who are unvaccinated.
Masks also provide additional protection for the wearer, even those who are fully vaccinated. Vaccines have been very effective, even against the Delta variant, in protecting against severe infection, hospitalization, and death. However, the Delta variant has led to a number of breakthrough infections in people who are fully vaccinated, and masks provide another layer of protection.
To check the level of virus transmission in your area, visit the CDC’s COVID Data Tracker. Areas with substantial or high transmission appear in orange or red.
What is the new naming system for COVID-19 variants?
The WHO recently announced a new naming system for COVID-19 variants. The new names are intended to be easier to pronounce and will remove the stigma of a variant’s being associated with a particular country.
Under the new system, the variants will be named using letters of the Greek alphabet. For example:
- Alpha is the new name for the B.1.1.7 variant, first documented in the United Kingdom.
- Beta is the new name for the B.1.351 variant, first documented in South Africa.
- The P.1 variant, first documented in Brazil, will now be known as Gamma.
- The B.1.617.2 variant, first documented in India, will be called Delta.
For a complete list of new SARS-CoV-2 variant names, click here.
Scientists will likely continue referring to variants by strings of letters and numbers, which provide information about a variant’s lineage.
What are breakthrough infections, and why do they happen?
A breakthrough infection is one that occurs after full vaccination.
In an article published in MMWR, the CDC reported 10,262 breakthrough infections through the end of April 2021. By that point, more than 100 million Americans had received the COVID-19 vaccine.
The vast majority of breakthrough infections were asymptomatic, mild, or moderate. About 1,000 people with breakthrough infections were hospitalized, and 160 died, though the hospitalizations and deaths were not always related to COVID-19.
These numbers tell us that the vaccines are doing a good job preventing infection and severe illness. None of the vaccines were 100% effective in clinical trials, so a small number of breakthrough infections was expected.
- Wondering about COVID-19 vaccines if you're breastfeeding?
- Unvaccinated and misunderstood? Let's talk
- New information for parents on myocarditis and COVID-19 vaccines
- Children not yet vaccinated against COVID-19? What to do
- COVID-19 vaccines: Safe and effective for American Indian and Alaskan Native communities
- Should we track all breakthrough cases of COVID-19?
- The pandemic isn't over — particularly for people with disabilities
- World Health Organization
- Johns Hopkins University COVID-19 Interactive Map
- Harvard Medical School's HMX Online Learning team is offering a selection of immunity-related videos and interactive materials to help with understanding how the body reacts to threats like the coronavirus that causes COVID-19.
- Resources on Health Disparities and COVID-19
Interested in participating in COVID-19 research by tracking daily symptoms through a simple app? Help doctors and scientists at Massachusetts General Hospital and Harvard T.H. Chan School of Public Health study the symptoms of COVID-19 and track the spread of this virus by downloading the COVID Symptom Study app.
aerosols: infectious viral particles that can float or drift around in the air. Aerosols are emitted by a person infected with coronavirus — even one with no symptoms — when they talk, breathe, cough, or sneeze. Another person can breathe in these aerosols and become infected with the virus. Aerosolized coronavirus can remain in the air for up to three hours. A mask can help prevent that spread.
antibodies: proteins made by the immune system to fight infections. If the antibodies later encounter the same infection, they help prevent illness by recognizing the microbe and preventing it from entering cells.
antibody test: also known as a serologic test, an antibody test is a blood test that looks for antibodies created by your immune system. An antibody test can indicate if you were previously infected but is not a reliable way to determine whether you are currently infected.
antigen: a substance displayed on the surface of a microbe that stimulates the body to produce an immune response.
antigen test: a diagnostic test that detects specific proteins on the surface of the virus.
community spread (community transmission): is said to have occurred when people have been infected without any knowledge of contact with someone who has the same infection
contact tracing: a process that begins with identifying everyone a person diagnosed with a given illness (in this case COVID-19) has been in contact with since they became contagious. The contacts are notified that they are at risk, and may include those who share the person's home, as well as people who were in the same place around the same time as the person with COVID-19 — a school, office, restaurant, or doctor's office, for example. Contacts may be quarantined or asked to isolate themselves if they start to experience symptoms, and are more likely to be tested for coronavirus if they begin to experience symptoms.
containment: refers to limiting the spread of an illness. Because no vaccines exist to prevent COVID-19 and no specific therapies exist to treat it, containment is done using public health interventions. These may include identifying and isolating those who are ill, and tracking down anyone they have had contact with and possibly placing them under quarantine.
diagnostic test: indicates whether you are currently infected with COVID-19. A sample is collected using a swab of your nose, your nose and throat, or your saliva. The sample is then checked for the virus's genetic material (PCR test) or for specific viral proteins (antigen test).
effectiveness: indicates the benefit of a vaccine in the real world.
efficacy: indicates the benefit of a vaccine compared to a placebo in the context of a clinical trial.
epidemic: a disease outbreak in a community or region
flattening the curve: refers to the epidemic curve, a statistical chart used to visualize the number of new cases over a given period of time during a disease outbreak. Flattening the curve is shorthand for implementing mitigation strategies to slow things down, so that fewer new cases develop over a longer period of time. This increases the chances that hospitals and other healthcare facilities will be equipped to handle any influx of patients.
false negative: a test result that mistakenly indicates you are not infected when you are.
false positive: a test result that mistakenly indicates you are infected when you are not.
herd immunity: herd immunity occurs when enough people become immune to a disease to make its spread unlikely. As a result, the entire community is protected, even those who are not themselves immune. Herd immunity is usually achieved through vaccination, but it can also occur through natural infection.
immunity: partial or complete protection from a specific infection because a person has either had that infection previously or has been vaccinated against it.
incubation period: the period of time between exposure to an infection and when symptoms begin
isolation: the separation of people with a contagious disease from people who are not sick
long-haulers: people who have not fully recovered from COVID-19 weeks or even months after first experiencing symptoms.
mitigation: refers to steps taken to limit the impact of an illness. Because no vaccines exist to prevent COVID-19 and no specific therapies exist to treat it, mitigation strategies may include frequent and thorough handwashing, not touching your face, staying away from people who are sick, social distancing, avoiding large gatherings, and regularly cleaning frequently touched surfaces and objects at home, in schools, at work, and in other settings.
mutation: A change to a virus’s genetic material that occurs when the virus is replicating. The change is passed on to future generations of the virus.
monoclonal antibodies: laboratory-produced proteins designed to mimic naturally occurring antibodies that target specific antigens on viruses, bacteria, and cancer cells.
mRNA: short for messenger ribonucleic acid, mRNA is genetic material that contains instructions for making proteins.
mRNA vaccines: mRNA vaccines for COVID-19 contain synthetic mRNA. Inside the body, the mRNA enters human cells and instructs them to produce the "spike" protein found on the surface of the COVID-19 virus. The body recognizes the spike protein as an invader, and produces antibodies against it. If the antibodies later encounter the actual virus, they are ready to recognize and destroy it before it causes illness.
pandemic: a disease outbreak affecting large populations or a whole region, country, or continent
physical distancing: also called social distancing, refers to actions taken to stop or slow down the spread of a contagious disease. For an individual, it refers to maintaining enough physical distance (a minimum of six feet) between yourself and another person to reduce the risk of breathing in droplets or aerosols that are produced when an infected person breathes, talks, coughs, or sneezes.
polymerase chain reaction (PCR) test: a diagnostic test that detects the presence of the virus's genetic material.
post-viral syndrome: the constellation of symptoms experienced by COVID-19 long haulers. These symptoms may include fatigue, brain fog, shortness of breath, chills, body ache, headache, joint pain, chest pain, cough, and lingering loss of taste or smell.
presumptive positive test result: a positive test for the virus that causes COVID-19, performed by a local or state health laboratory, is considered "presumptive" until the result is confirmed by the CDC. While awaiting confirmation, people with a presumptive positive test result will be considered to be infected.
quarantine: separates and restricts the movement of people who have a contagious disease, have symptoms that are consistent with the disease, or were exposed to a contagious disease, to see if they become sick
SARS-CoV-2: short for severe acute respiratory syndrome coronavirus 2, SARS-CoV-2 is the official name for the virus responsible for COVID-19.
social distancing: also called physical distancing, refers to actions taken to stop or slow down the spread of a contagious disease. For an individual, it refers to maintaining enough physical distance (a minimum of six feet) between yourself and another person to reduce the risk of breathing in droplets or aerosols that are produced when an infected person breathes, talks, coughs, or sneezes. It is possible to safely maintain social connections while social distancing, through phone calls, video chats, and social media platforms.
spike protein: a protein on the surface of the SARS-CoV-2 virus that binds to and allows the virus to enter human cells.
variant: A virus containing one or more mutations that make it different from a version of the virus that has been circulating.
variants of concern: SARS-CoV-2 viruses with mutations that make them more likely to spread, evade vaccines, or make people sicker.
vector: a harmless capsule. In a vaccine, a vector may be used to deliver a substance into the body in order to prompt an immune response.
virus: a virus is the smallest of infectious microbes, smaller than bacteria or fungi. A virus consists of a small piece of genetic material (DNA or RNA) surrounded by a protein shell. Viruses cannot survive without a living cell in which to reproduce. Once a virus enters a living cell (the host cell) and takes over a cell's inner workings, the cell cannot carry out its normal life-sustaining tasks. The host cell becomes a virus manufacturing plant, making viral parts that then reassemble into whole viruses and go on to infect other cells. Eventually, the host cell dies.
Image: Naeblys/Getty Images
Harvard Health Publishing Coronavirus Resource Center Experts
The Harvard Health Publishing team would like to acknowledge the Harvard Medical School experts who have contributed their time and expertise: Steven A. Adelman, MD; Ashwini Bapat, MD; Nicole Baumer, MD, MEd; Suzanne Bertisch, MD, MPH; Joseph R. Betancourt, MD, MPH; Barry R. Bloom, PhD; Emeric Bojarski, MD; Melissa Brodrick, MEd; Andrew E. Budson, MD; Stephanie Collier, MD, MPH; Todd Ellerin, MD; Huma Farid, MD; Robert Gabbay, MD, PhD, FACP; Alan Geller, MPH, RN; Ellen S. Glazer, LICSW; David C. Grabowski, PhD; Shelly Greenfield, MD, MPH; Ilona T. Goldfarb, MD, MPH; Peter Grinspoon, MD; Abraar Karan, MD, MPH, DTM&H; Sabra L. Katz-Wise, PhD; Alyson Kelley-Hedgepeth, MD; Anthony Komaroff, MD; Douglas Krakower, MD; Debi LaPlante, PhD; Howard E. LeWine, MD; Dara K. Lee Lewis, MD; Sharon Levy, MD, MPH; Kristina Liu, MD, MHS; Julia Marcus, PhD, MPH; Luana Marques, PhD; Claire McCarthy, MD; Chris McDougle, MD; Babar Memon, MD, MSc; Kristin Moffitt, MD; Uma Naidoo, MD; Janelle Nassim, MD; Justin Neiman; Vikram Patel, MBBS, PhD; Edward Phillips, MD; Shiv Pillai, PhD, MBBS; John Ross, MD, FIDSA; Lee H. Schwamm, MD; Catherine Ullman Shade, PhD, MEd; Howard J. Shaffer, PhD, CAS; Roger Shapiro, MD, MPH; John Sharp, MD; Amy C. Sherman, MD; Robert H. Shmerling, MD; Jacqueline Sperling, PhD; Fatima Cody Stanford, MD, MPH, MPA, FAAP, FACP, FTOS; Dawn Sugarman, PhD; Monique Tello, MD, MPH; Robyn Thom, MD; Karen Turner, OTR/L; Rochelle Wallensky, MD, MPH; Janice Ware, PhD; Bobbi Wegner, PsyD; Scott Weiner, MD; Sarah Wilkie, MS; Anna R. Wolfson, MD.
As a service to our readers, Harvard Health Publishing provides access to our library of archived content. Please note the date of last review or update on all articles. No content on this site, regardless of date, should ever be used as a substitute for direct medical advice from your doctor or other qualified clinician.